

Union Calendar No. 196

112TH CONGRESS
1ST SESSION

H. R. 1254

[Report No. 112–295, Parts I and II]

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

IN THE HOUSE OF REPRESENTATIVES

MARCH 30, 2011

Mr. DENT (for himself, Mr. MEEHAN, Mr. MARINO, Mr. PLATTS, Mr. BARLETTA, Mr. CUELLAR, Mrs. EMERSON, Mrs. BIGGERT, Mr. LATOURETTE, Mr. GIBSON, Mr. STIVERS, and Mr. REED) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

NOVEMBER 22, 2011

Reported from the Committee on Energy and Commerce with an amendment

[Strike out all after the enacting clause and insert the part printed in *italic*]

NOVEMBER 22, 2011

Additional sponsors: Mr. HOLDEN, Mr. BOSWELL, Mr. LATHAM, Mr. LOEBSACK, Mr. DEFAZIO, Mr. DOLD, Mr. LANCE, Mr. MURPHY of Pennsylvania, Mrs. BONO MACK, Mr. MICHAUD, Ms. PINGREE of Maine, and Mr. GOWDY

NOVEMBER 22, 2011

Reported from the Committee on the Judiciary with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

[Strike out all after the enacting clause and insert the part printed in **boldface roman**]

[For text of introduced bill, see copy of bill as introduced on March 30, 2011]

A BILL

To amend the Controlled Substances Act to place synthetic
drugs in Schedule I.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 *This Act may be cited as the “Synthetic Drug Control*
5 *Act of 2011”.*

6 **SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I**
7 **OF THE CONTROLLED SUBSTANCES ACT.**

8 (a) *CANNABIMIMETIC AGENTS.*—*Schedule I, as set*
9 *forth in section 202(c) of the Controlled Substances Act (21*
10 *U.S.C. 812(c)) is amended by adding at the end the fol-*
11 *lowing:*

12 *“(d)(1) Unless specifically exempted or unless listed in*
13 *another schedule, any material, compound, mixture, or*
14 *preparation which contains any quantity of*
15 *cannabimimetic agents, or which contains their salts, iso-*
16 *mers, and salts of isomers whenever the existence of such*
17 *salts, isomers, and salts of isomers is possible within the*
18 *specific chemical designation.*

19 *“(2) In paragraph (1):*

20 *“(A) The term ‘cannabimimetic agents’ means*
21 *any substance that is a cannabinoid receptor type 1*
22 *(CB1 receptor) agonist as demonstrated by binding*
23 *studies and functional assays within any of the fol-*
24 *lowing structural classes:*

1 “(i) 2-(3-hydroxycyclohexyl)phenol with
2 substitution at the 5-position of the phenolic ring
3 by alkyl or alkenyl, whether or not substituted on
4 the cyclohexyl ring to any extent.

5 “(ii) 3-(1-naphthoyl)indole or 3-(1-
6 naphthylmethane)indole by substitution at the
7 nitrogen atom of the indole ring, whether or not
8 further substituted on the indole ring to any ex-
9 tent, whether or not substituted on the naphthoyl
10 or naphthyl ring to any extent.

11 “(iii) 3-(1-naphthoyl)pyrrole by substi-
12 tution at the nitrogen atom of the pyrrole ring,
13 whether or not further substituted in the pyrrole
14 ring to any extent, whether or not substituted on
15 the naphthoyl ring to any extent.

16 “(iv) 1-(1-naphthylmethylene)indene by sub-
17 stitution of the 3-position of the indene ring,
18 whether or not further substituted in the indene
19 ring to any extent, whether or not substituted on
20 the naphthyl ring to any extent.

21 “(v) 3-phenylacetylindole or 3-benzoylindole
22 by substitution at the nitrogen atom of the indole
23 ring, whether or not further substituted in the
24 indole ring to any extent, whether or not sub-
25 stituted on the phenyl ring to any extent.

1 “(B) Such term includes—

2 “(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
3 hydroxycyclohexyl]-phenol (CP-47,497);

4 “(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-
5 hydroxycyclohexyl]-phenol (cannabicyclohexanol
6 or CP-47,497 C8-homolog);

7 “(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH-
8 018 and AM678);

9 “(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-
10 073);

11 “(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-
12 019);

13 “(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph-
14 thoyl)indole (JWH-200);

15 “(vii) 1-pentyl-3-(2-
16 methoxyphenylacetyl)indole (JWH-250);

17 “(viii) 1-pentyl-3-[1-(4-
18 methoxynaphthoyl)]indole (JWH-081);

19 “(ix) 1-pentyl-3-(4-methyl-1-naph-
20 thoyl)indole (JWH-122);

21 “(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole
22 (JWH-398);

23 “(xi) 1-(5-fluoropentyl)-3-(1-naph-
24 thoyl)indole (AM2201);

1 “(xii) 1-(5-fluoropentyl)-3-(2-
2 iodobenzoyl)indole (AM694);

3 “(xiii) 1-pentyl-3-[(4-methoxy)-ben-
4 zoyl]indole (SR-19 and RCS-4);

5 “(xiv) 1-cyclohexylethyl-3-(2-
6 methoxyphenylacetyl)indole (SR-18 and RCS-8);

7 and

8 “(xv) 1-pentyl-3-(2-
9 chlorophenylacetyl)indole (JWH-203).”.

10 (b) *OTHER DRUGS.*—Schedule I of section 202(c) of
11 *the Controlled Substances Act (21 U.S.C. 812(c)) is amend-*
12 *ed in subsection (c) by adding at the end the following:*

13 “(18) 4-methylmethcathinone (Mephedrone).

14 “(19) 3,4-methylenedioxyprovalerone (MDPV).

15 “(20) 3,4-methylenedioxyethcathinone
16 (methylone).

17 “(21) Naphthylpyrovalerone (naphyrone).

18 “(22) 4-fluoromethcathinone (flephedrone).

19 “(23) 4-methoxymethcathinone (methedrone; Bk-
20 PMMA).

21 “(24) Ethcathinone (N-Ethylcathinone).

22 “(25) 3,4-methylenedioxyethcathinone (ethylone).

23 “(26) Beta-keto-N-methyl-3,4-
24 benzodioxypolybutanamine (butylone).

25 “(27) N,N-dimethylcathinone (metamfepramone).

1 “(28) *Alpha-pyrrolidinopropiophenone (alpha-*
2 *PPP).*”

3 “(29) *4-methoxy-alpha-pyrrolidinopropiophenone*
4 *(MOPPP).*”

5 “(30) *3,4-methylenedioxy-alpha-*
6 *pyrrolidinopropiophenone (MDPPP).*”

7 “(31) *Alpha-pyrrolidinovalerophenone (alpha-*
8 *PVP).*”

9 “(32) *6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-*
10 *6-amine) (MDAI).*”

11 “(33) *3-fluoromethcathinone.*”

12 “(34) *4'-Methyl- α -pyrrolidinobutiophenone*
13 *(MPBP).*”

14 **SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT**
15 **HAZARDS TO PUBLIC SAFETY EXPANSION.**

16 *Section 201(h)(2) of the Controlled Substances Act (21*
17 *U.S.C. 811(h)(2)) is amended—*

18 (1) *by striking “one year” and inserting “2*
19 *years”; and*

20 (2) *by striking “six months” and inserting “1*
21 *year”.*

22 **SECTION 1. SHORT TITLE.**

23 **This Act may be cited as the “Synthetic**
24 **Drug Control Act of 2011”.**

1 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I
2 OF THE CONTROLLED SUBSTANCES ACT.

3 (a) CANNABIMIMETIC AGENTS.—Schedule I,
4 as set forth in section 202(c) of the Controlled
5 Substances Act (21 U.S.C. 812(c)) is amended
6 by adding at the end the following:

7 “(d)(1) Unless specifically exempted or un-
8 less listed in another schedule, any material,
9 compound, mixture, or preparation which
10 contains any quantity of cannabimimetic
11 agents, or which contains their salts, isomers,
12 and salts of isomers whenever the existence
13 of such salts, isomers, and salts of isomers is
14 possible within the specific chemical designa-
15 tion.

16 “(2) In paragraph (1):

17 “(A) The term ‘cannabimimetic
18 agents’ means any substance that is a
19 cannabinoid receptor type 1 (CB1 recep-
20 tor) agonist as demonstrated by binding
21 studies and functional assays within any
22 of the following structural classes:

23 “(i) 2-(3-hydroxycyclohexyl)phenol
24 with substitution at the 5-position of
25 the phenolic ring by alkyl or alkenyl,

1 **whether or not substituted on the**
2 **cyclohexyl ring to any extent.**

3 **“(ii) 3-(1-naphthoyl)indole or 3-(1-**
4 **naphthylmethane)indole by substi-**
5 **tution at the nitrogen atom of the**
6 **indole ring, whether or not further**
7 **substituted on the indole ring to any**
8 **extent, whether or not substituted on**
9 **the naphthoyl or naphthyl ring to any**
10 **extent.**

11 **“(iii) 3-(1-naphthoyl)pyrrole by**
12 **substitution at the nitrogen atom of**
13 **the pyrrole ring, whether or not fur-**
14 **ther substituted in the pyrrole ring to**
15 **any extent, whether or not sub-**
16 **stituted on the naphthoyl ring to any**
17 **extent.**

18 **“(iv) 1-(1-**
19 **naphthylmethylene)indene by substi-**
20 **tution of the 3-position of the indene**
21 **ring, whether or not further sub-**
22 **stituted in the indene ring to any ex-**
23 **tent, whether or not substituted on**
24 **the naphthyl ring to any extent.**

1 “(v) 3-phenylacetylindole or 3-
2 benzoylindole by substitution at the
3 nitrogen atom of the indole ring,
4 whether or not further substituted in
5 the indole ring to any extent, whether
6 or not substituted on the phenyl ring
7 to any extent.

8 “(B) Such term includes—

9 “(i) 5-(1,1-dimethylheptyl)-2-
10 [(1R,3S)-3-hydroxycyclohexyl]-phenol
11 (CP-47,497);

12 “(ii) 5-(1,1-dimethyloctyl)-2-
13 [(1R,3S)-3-hydroxycyclohexyl]-phenol
14 (cannabicyclohexanol or CP-47,497
15 C8-homolog);

16 “(iii) 1-pentyl-3-(1-naph-
17 thoyl)indole (JWH-018 and AM678);

18 “(iv) 1-butyl-3-(1-naphthoyl)indole
19 (JWH-073);

20 “(v) 1-hexyl-3-(1-naphthoyl)indole
21 (JWH-019);

22 “(vi) 1-[2-(4-morpholinyl)ethyl]-3-
23 (1-naphthoyl)indole (JWH-200);

- 1 “(vii) **1-pentyl-3-(2-**
2 **methoxyphenylacetyl)indole (JWH-**
3 **250);**
- 4 “(viii) **1-pentyl-3-[1-(4-**
5 **methoxynaphthoyl)]indole (JWH-081);**
- 6 “(ix) **1-pentyl-3-(4-methyl-1-naph-**
7 **thoyl)indole (JWH-122);**
- 8 “(x) **1-pentyl-3-(4-chloro-1-naph-**
9 **thoyl)indole (JWH-398);**
- 10 “(xi) **1-(5-fluoropentyl)-3-(1-naph-**
11 **thoyl)indole (AM2201);**
- 12 “(xii) **1-(5-fluoropentyl)-3-(2-**
13 **iodobenzoyl)indole (AM694);**
- 14 “(xiii) **1-pentyl-3-[(4-methoxy)-ben-**
15 **zoyl]indole (SR-19 and RCS-4);**
- 16 “(xiv) **1-cyclohexylethyl-3-(2-**
17 **methoxyphenylacetyl)indole (SR-18**
18 **and RCS-8); and**
- 19 “(xv) **1-pentyl-3-(2-**
20 **chlorophenylacetyl)indole (JWH-**
21 **203).”.**

22 **(b) OTHER DRUGS.—Schedule I of section**
23 **202(c) of the Controlled Substances Act (21**
24 **U.S.C. 812(c)) is amended in subsection (c) by**
25 **adding at the end the following:**

1 **“(18) 4-methylmethcathinone**
2 **(Mephedrone).**

3 **“(19) 3,4-methylenedioxyprovalerone**
4 **(MDPV).**

5 **“(20) 3,4-**
6 **methylenedioxyethcathinone**
7 **(methydone).**

8 **“(21) Naphthylpyrovalerone**
9 **(naphyrone).**

10 **“(22) 4-fluoromethcathinone**
11 **(flepheprone).**

12 **“(23) 4-methoxymethcathinone**
13 **(methedrone; Bk-PMMA).**

14 **“(24) Ethcathinone (N-**
15 **Ethylcathinone).**

16 **“(25) 3,4-methylenedioxyethylcathinone**
17 **(ethylone).**

18 **“(26) Beta-keto-N-methyl-3,4-**
19 **benzodioxymethylbutanamine (butylone).**

20 **“(27) N,N-dimethylcathinone**
21 **(metamfepramone).**

22 **“(28) Alpha-**
23 **pyrrolidinopropiophenone (alpha-PPP).**

24 **“(29) 4-methoxy-alpha-**
25 **pyrrolidinopropiophenone (MOPPP).**

- 1 **“(30) 3,4-methylenedioxy-**
2 **alphapyrrolidinopropiophenone**
3 **(MDPPP).**
- 4 **“(31) Alpha-pyrrolidinovalerophenone**
5 **(alpha-PVP).**
- 6 **“(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-**
7 **dioxol-6-amine) (MDAI).**
- 8 **“(33) 3-fluoromethcathinone.**
- 9 **“(34) 4'-Methyl- α -**
10 **pyrrolidinobutiophenone (MPBP).**
- 11 **“(35) 2-(2,5-Dimethoxy-4-**
12 **ethylphenyl)ethanamine (2C-E).**
- 13 **“(36) 2-(2,5-Dimethoxy-4-**
14 **methylphenyl)ethanamine (2C-D).**
- 15 **“(37) 2-(4-Chloro-2,5-**
16 **dimethoxyphenyl)ethanamine (2C-C).**
- 17 **“(38) 2-(4-Iodo-2,5-**
18 **dimethoxyphenyl)ethanamine (2C-I).**
- 19 **“(39) 2-[4-(Ethylthio)-2,5-**
20 **dimethoxyphenyl]ethanamine (2C-T-2).**
- 21 **“(40) 2-[4-(Isopropylthio)-2,5-**
22 **dimethoxyphenyl]ethanamine (2C-T-4).**
- 23 **“(41) 2-(2,5-**
24 **Dimethoxyphenyl)ethanamine (2C-H).**

1 **“(42) 2-(2,5-Dimethoxy-4-nitro-**
2 **phenyl)ethanamine (2C-N).**

3 **“(43) 2-(2,5-Dimethoxy-4-(n)-**
4 **propylphenyl)ethanamine (2C-P).”.**

5 **SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT**
6 **HAZARDS TO PUBLIC SAFETY EXPANSION.**

7 **Section 201(h)(2) of the Controlled Sub-**
8 **stances Act (21 U.S.C. 811(h)(2)) is amended—**

9 **(1) by striking “one year” and insert-**
10 **ing “2 years”; and**

11 **(2) by striking “six months” and in-**
12 **serting “1 year”.**

Union Calendar No. 196

112TH CONGRESS
1ST Session

H. R. 1254

[Report No. 112-295, Parts I and II]

A BILL

To amend the Controlled Substances Act to place
synthetic drugs in Schedule I.

NOVEMBER 22, 2011

Reported from the Committee on Energy and Commerce
with an amendment

NOVEMBER 22, 2011

Reported from the Committee on the Judiciary with an
amendment, committed to the Committee of the Whole
House on the State of the Union, and ordered to be
printed